Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease

References

• Peach MJ. Renin–angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313–370.
   PubMed Web of Science ®Google Scholar
• Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA. 1995;92:3521–3525.
   PubMed Web of Science ®Google Scholar
• Lavoie JL, Sigmund CD. Minireview: overview of the renin–angiotensin system—an endocrine and paracrine system. Endocrinology. 2003;144:2179–2183.
   PubMed Web of Science ®Google Scholar
• Heeg JE, de Zeeuw D, de Jong PE. Antiproteinuric effect of ACE inhibitors. Lancet. 1988;2:1251–1252.
   PubMed Web of Science ®Google Scholar
• Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313:1617–1620.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345–1350.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin–angiotensin system inhibition. Ann Intern Med. 2002;136:604–615.
   PubMed Web of Science ®Google Scholar
• Márquez DF, Ruiz-Hurtado G, Ruilope LM, et al. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16:2283–2292.
   PubMed Web of Science ®Google Scholar
• Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7:493–504.
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705.
   PubMed Web of Science ®Google Scholar
• Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–3133.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374:1521–1532.
   PubMed Web of Science ®Google Scholar
• Woo KT, Choong HL, Wong KS, et al. Aliskiren and losartan trial in non-diabetic chronic kidney disease. Renin–Angiotensin–Aldosterone Syst. 2014;15:515–522.
   PubMed Web of Science ®Google Scholar
• Mihai G, Varghese J, Kampfrath T, et al. Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial. J Am Heart Assoc. 2013;2:e004879.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Persson F, Brenner BM, et al. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:309–317.
   PubMed Web of Science ®Google Scholar
• Soji K, Doi S, Nakashima A, et al. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study. Clin Exp Nephrol. 2015;19:631–638.
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–2213.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Bakris GL, Abraham WT, et al. Complete renin–angiotensin–aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013;62:444–449.
   PubMed Web of Science ®Google Scholar
• Moniwa N, Varagic J, Ahmad S, et al. Hemodynamic and hormonal changes to dual renin–angiotensin system inhibition in experimental hypertension. Hypertension. 2013;61:417–424.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529–538.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Higashi Y, Nakagawa K, et al. Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension. 2001;38:90–94.
   PubMed Web of Science ®Google Scholar
• Carver KA, Smith TL, Gallagher PE, et al. Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation. 2015;22:19–27.
   PubMed Web of Science ®Google Scholar
• Porrello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958–972.
   Web of Science ®Google Scholar
• Ewert S, Laesser M, Johansson B, et al. The angiotensin II receptor type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa. BMC Pharmacol. 2003;3:2.
   PubMedGoogle Scholar
• Yugandhar VG, Clark MA. Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Peptides. 2013;46:26–32.
   PubMed Web of Science ®Google Scholar
• Gard PR. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 2008;9 Suppl 2:S15.
   PubMed Web of Science ®Google Scholar
• Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the renin–angiotensin–aldosterone system, and the heart. Arch Intern Med. 2004;164:1737–1748.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Kovarik JJ, Antlanger M, Domenig O, et al. Molecular regulation of the renin–angiotensin system in haemodialysis patients. Nephrol Dial Transplant. 2015;30:115–123.
   PubMed Web of Science ®Google Scholar
• Sharp S, Poglitsch M, Zilla P, et al. Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin–angiotensin system in myocardial infarcted rats. Renin–Angiotensin–Aldosterone Syst. 2015;16:1149–1158.
   PubMed Web of Science ®Google Scholar
• Poglitsch M, Domenig O, Schwager C, et al. Recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin–angiotensin-system. Int J Hypertens. 2012;2012:428950.
   PubMedGoogle Scholar
• Ye M, Wysocki J, Gonzalez-Pacheco FR, et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension. 2012;60:730–740.
   PubMed Web of Science ®Google Scholar
• Haber PK, Ye M, Wysocki J, et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014;63:774–782.
   PubMed Web of Science ®Google Scholar
• Croghan CW, Egeghy PP. Methods of dealing with values below the limit of detection using SAS. 2003. Available from: analytics.ncsu.edu/sesug/2003/SD08-Croghan.pdf2003.
   Google Scholar
• Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199–3205.
   PubMed Web of Science ®Google Scholar
• Simões e Silva AC, Silveira KD, et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169:477–492.
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828.
   PubMed Web of Science ®Google Scholar
• Santos RA, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin–angiotensin system. J Endocrinol. 2013;216:R1–R17.
   PubMed Web of Science ®Google Scholar
• Wenzel UO, Krebs C, Benndorf R. The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst. 2010;11:37–41.
   PubMed Web of Science ®Google Scholar
• Bomback AS, Rekhtman Y, Klemmer PJ, et al. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens. 2012;6:338–345.
   PubMed Web of Science ®Google Scholar
• Poglitsch M, Ahmed AH, Resl M, et al. OS 35-04 the AA2-ratio: towards improved screening for primary aldosteronism in hypertension. J Hypertens. 2016;34 Suppl 1:e400.
   Google Scholar
• Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649–1654.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699–705.
   PubMed Web of Science ®Google Scholar
• Aulakh GK, Sodhi RK, Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007;81:615–639.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension. 2008;51:15–18.
   PubMed Web of Science ®Google Scholar
• Holmer SR, Hense HW, Danser AH, et al. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart. 1998;80:45–48.
   PubMed Web of Science ®Google Scholar
• Holmer SR, Hengstenberg C, Mayer B, et al. Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade. J Intern Med. 2001;249:167–172.
   PubMed Web of Science ®Google Scholar